The Merck Group Website
The Merck Group Website
 
 

Merck Serono Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide

Merck Serono is the first and only multinational company in China to dedicate a large scale green-field investment to the production of pharmaceuticals on China’s essential drug list. The facility is designed to comply with the highest international standards in terms of quality, environment, health and safety.

Merck Serono Launches New Software and Updated Device for Multiple Sclerosis Patients

Merck has launched the new RebiSmart® and MSdialog™ in 15 countries. The updated device and first-of-its-kind web-based software platform are designed to engage multiple sclerosis patients and health care providers, and provide them with injection history, treatment adherence information and health reports.

Innovation in Growth Hormones

The latest innovation in the treatment of Growth Hormone Deficiency (GHD): an updated version of the easypod™ system for markets in Europe has been launched.

The easypod™ system is the only electronic, fully automated recombinant human growth hormone injection device that provides accurate adherence data on screen, which enables physicians managing patients requiring growth hormone to have a clearer picture to make the best informed treatment decisions.

Commited to Innovation

Merck Serono is committed to innovation in science that will make a meaningful difference in the lives of people living with serious medical needs across our therapeutic areas of focus.

Corporate Responsibility

Corporate Responsibility is an integral part of our corporate culture.

Merck Serono has dedicated itself to improving access to health for underserved populations.
 

Transforming lives through medical science

As the biopharmaceutical division of Merck, we have an enduring commitment to transform lives through innovative medicines and high-value solutions.

Merck Serono focuses on areas of high unmet medical needs and is a leader in providing differentiated medicines to help improve patient outcomes  in key areas such as
  • cancer
  • multiple sclerosis
  • infertility
  • endocrine and metabolic disorders
  • cardiovascular diseases